We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 6,051

Patent settlements as an endangered species: DG Comp's latest monitoring exercise on patent settlements in Europe
  • White & Case LLP
  • European Union
  • December 20 2013

On 9 December 2013, DG Comp published its fourth report on the monitoring in Europe of patent settlements. Like its predecessors, the report welcomes

It doesn’t matter what you call it; “co-promotion” agreement fined as a cartel
  • McGuireWoods LLP
  • European Union
  • January 2 2014

On 10 December 2013, the EC imposed fines of EUR10.8 million on Johnson & Johnson (J&J) and EUR5.5 million on Novartis for an "intolerable" agreement

Overhaul of EU medical device and diagnostic legislation faces further delays
  • Sidley Austin LLP
  • European Union
  • December 13 2013

The latest December 10, 2013 discussions between EU Member States on new EU medical device and in vitro diagnostic (IVD) regulations reveal continued

Bioinformatics patents a new challenge for patent offices
  • Marks & Clerk
  • European Union, United Kingdom
  • December 17 2013

The number of bioinformatics patent applications being filed, although still relatively small, has been steadily increasing over the past few years

Advocate General Jääskinen gives Georgetown University SPC opinion
  • McDermott Will & Emery
  • European Union, Netherlands, United Kingdom
  • December 16 2013

On 14 November 2013, Advocate General (AG) Jääskinen's opinion in the Dutch supplementary protection certificate (SPC) referral, Georgetown

European markets less than enthusiastic over biosimilars
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • December 12 2013

While Europe has had a regulatory approval pathway for biosimilar drug products for some years, their use reportedly remains anemic. Physicians are

Outside of FDA
  • Drinker Biddle & Reath LLP
  • European Union, Global, United Kingdom, USA
  • June 30 2008

The European Directorate for the Quality of Medicines & HealthCare (EDQM, Council of Europe), recently met with the Ministry of Health of India and the Indian Pharmacopoeia Commission (IPC) to discuss improving the quality and safety of medicines in both locations, and developing joint inspections of DBR Reg Sci May - June 2008 Page 7 manufacturing sites

Brexit - A Hard Landing? Potential Impacts on the UK Pharmaceutical Sector
  • Pillsbury Winthrop Shaw Pittman LLP
  • European Union, United Kingdom
  • October 11 2016

The UK’s pharmaceutical sector may have more to fear than other sectors from a possible “hard-Brexit,” with the potential for the UK’s withdrawal from

Opening Life Sciences’ Unified Patent Court war chest
  • Bristows LLP
  • European Union, United Kingdom
  • October 11 2016

The future role of the UK in the Unified Patent Court (UPC), if any, has been brought to the forefront as the battle on the fate of the UPC in a

WannaCry cyber-attack: how will impending new laws affect security obligations and regulatory risk?
  • Osborne Clarke
  • European Union, United Kingdom
  • May 18 2017

An unprecedented cyber-attack on 12 May 2017, which affected over 45,000 organisations globally, provides yet another stark example of why all